INMUNE BIO INC (INMB) Stock Analyst Ratings
NASDAQ:INMB - Nasdaq - US45782T1051 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 84% to INMB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 23.87. This target is 209.97% above the current price.
INMB was analyzed by 11 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about INMB.
In the previous month the buy percentage consensus was at a similar level.
INMB was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-02-13 | Maxim Group | Maintains | Buy -> Buy |
| 2025-02-11 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-10-21 | Alliance Global Partners | Initiate | Buy |
| 2024-09-27 | Raymond James | Initiate | Outperform |
| 2024-08-22 | ScotiaBank | Initiate | Sector Outperform |
| 2023-06-01 | Baird | Initiate | Outperform |
| 2022-05-24 | BTIG | Maintains | Buy |
| 2022-05-24 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2022-01-24 | B. Riley Securities | Maintains | Buy |
| 2021-04-21 | B. Riley FBR | Initiate | Buy |